72
SRX Global to acquire CERo Therapeutics for stock and ~$9.8M debt forgiveness
Why it matters
SRX Global signed a definitive agreement to acquire CERo Therapeutics' operating subsidiary from its parent CERo Therapeutics Holdings, with consideration consisting of $1M in SRXH stock (at lower of prior-day close or 20-day VWAP), forgiveness of $8.25M in outstanding debt plus accrued interest, and assumption of ~$1.56M in liabilities. The transaction is subject to a 30-day go-shop period and superior proposal rights, creating execution risk through at least mid-March 2027.
In plain language
SRXH is buying another company for mostly a debt write-off and some of its own stock, but the deal can still be shopped around for 30 days—so it might not happen or the terms could change.
Exposure
Price check
not measured: no fresh price at the time of scoringHow this is measured
Information only. AURA does not give buy or sell recommendations.